DJIA 16,979.13 59.54 0.35%
NASDAQ 4,526.48 -1.03 -0.02%
S&P 500 1,986.51 4.91 0.25%
market minute promo

Roche Holding Ltd. (ADR) (NASDAQOTH: RHHBY)

36.45 -0.19 (-0.52%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

RHHBY $36.45 -0.52%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $36.50
Previous Close $36.64
Daily Range $36.35 - $36.57
52-Week Range $30.91 - $38.71
Market Cap $204.9B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.5%)
Volume 322,573
Average Daily Volume 602,494
Current FY EPS $2.05

Sector

Healthcare

Industry

Pharmaceuticals

Roche Holding Ltd. (ADR) (RHHBY) Description

Website:

News & Commentary

Keep Calm and Carry On, Roche Stock

Roche continues to build upon the strongest oncology franchise in Big Pharma but could still use some non-oncology hits

FDA Approves Gilead Sciences Drug for 3 Cancers

The company's tablet, Zydelig, works by blocking signals inside some cancer cells that allow them to grow and survive.

Puma Biotechnology Inc's Overnight Triple is Just the Beginning

Pfizer gives Puma Biotechnology a gift, while Puma might be able to steal sales from Roche.

Is this Exelixis Stock's Worst Nightmare?

Exelixis has a great lineup of promising oncology candidates, but will it be able to develop them?

Should Roche Buy Exelixis?

A successful phase 3 study has started rumors that Roche may bid for Exelixis

Time to Fall Back in Love With Exelixis Inc.?

Good news from Exelixis' partner Roche, but we don't know if the trial data is good enough to beat GlaxoSmithKline's competing regimen.

Can Roche Find Rare Success In Alzheimer's?

Roche is about to release phase 2 data that could redefine its opportunity in this extremely hard-to-treat disease

Tuesday’s Top Biotech Stories: Johnson & Johnson, Roche, Novartis, Google

Johnson & Johnson, Roche, Novartis, Google are the top stocks to watch in health care this Tuesday morning.

Up 23%: Time to Buy Exelixis?

A great day today, but is it time to buy?

Why Exelixis Inc. Stock Soared

Exelixis shares shoot to the moon after the company delivers positive phase 3 data on its advanced melanoma combination therapy. See what this news means for investors.

See More RHHBY News...

RHHBY's Top Competitors

RHHBY $36.45 (-0.52%)
Current stock: RHHBY
JNJ $103.21 (0.24%)
Current stock: JNJ
PFE $28.89 (-0.17%)
Current stock: PFE
NVS $88.60 (-0.03%)
Current stock: NVS